# A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

> **NCT07283705** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Phase 2 Study
- BMS-986504
- MTAP-deleted Pancreatic Cancer

## Interventions

- **DRUG:** BMS-986504
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT07283705
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2029-10-01
- **Final completion:** 2031-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283705, "A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07283705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*